
Brown & Brown

WHITE PAPER

The Future of Medical Stop-Loss Reinsurance:

Growth, Risk, and Underwriting Discipline in a Hardening Market.





The medical stop-loss reinsurance market is entering a period of sustained growth, fueled by the continued expansion of employer-sponsored self-funded health plans and rising catastrophic healthcare costs. Although demand for stop-loss protection remains strong, insurers and reinsurers face mounting pressure from medical inflation, specialty pharmaceuticals, and costly gene and cell therapies that are increasing claim severity. In response, the market is moving toward firmer pricing, more disciplined underwriting, and greater use of predictive analytics. We will review the current market environment, key growth drivers, emerging risks, and the industry outlook over the next three to five years.

Introduction

Medical stop-loss insurance protects employers that self-fund employee health benefit plans by limiting their exposure to catastrophic medical claims. Stop-loss carriers often transfer part of this risk to reinsurers, creating a specialized reinsurance market that helps support financial stability in employer-sponsored healthcare.

Over the past decade, rising healthcare costs, demographic shifts, broader adoption of self-funded plans, and advances in medical technology have increased both the frequency and severity of large claims. These changes have reshaped underwriting practices and changed the industry's risk profile.

Market Growth and Demand

A primary driver of medical stop-loss reinsurance demand is the continued shift toward self-funded employer health plans. Employers favor self-funding because it allows more flexible plan design, greater visibility into healthcare spending, and potential long-term cost savings. As more organizations assume direct responsibility for healthcare expenses, demand for stop-loss coverage—and related reinsurance protection—continues to grow.

Industry forecasts suggest the broader health and medical reinsurance market will grow about 7–8 percent annually through the end of the decade. Medical stop-loss is among the fastest-growing segments, reflecting the increasing financial volatility of catastrophic healthcare claims.

Several structural factors support continued market expansion:

- Increasing adoption of self-funded health plans among small and mid-sized employers.
- Continued growth in healthcare expenditures.
- Greater financial exposure associated with catastrophic medical claims.
- Increasing utilization of advanced specialty pharmaceuticals and personalized medicine.

These trends suggest that premium volume will continue to increase even as underwriting conditions become more challenging.

Medical Inflation and Claims Severity

Although medical inflation has historically influenced insurance pricing, recent years have demonstrated that claims severity has become an even more significant concern than claim frequency. The cost of treating individual patients with complex medical conditions has increased substantially due to advances in biotechnology and pharmaceutical innovation.

Among the most important contributors to increasing claims severity are specialty pharmaceuticals, including biologic medications, oncology therapies, CAR-T cell therapies, and gene therapies. Several newly approved gene therapies now carry treatment costs exceeding $2 million per patient. Currently there are eight gene therapies that cost greater than $3 million per patient, while two therapies exceed $4 million per patient.



Unlike traditional catastrophic medical events, these therapies create concentrated financial exposure that can dramatically affect stop-loss carriers and their reinsurers. Consequently, underwriting models that relied primarily on historical claims experience require continual revision to account for emerging medical technologies.



Market Hardening and Underwriting Discipline

The medical stop-loss market has entered a period of a “hardening market.” After several years of competitive pricing and relatively soft underwriting standards, carriers have begun implementing significant changes designed to restore underwriting profitability. The expectation is that the hardening market will be at minimum a 2–3 year cycle before a return to a profitable state of the business.

Current underwriting trends include:

- Higher renewal premium increases.
- Increased specific deductible attachment points.
- More restrictive contract language.
- Greater scrutiny of pharmacy utilization.
- Enhanced review of claimant history.
- Individualized underwriting for higher-risk employer groups.

These measures reflect insurers’ recognition that historical pricing assumptions have become insufficient to offset rapidly increasing catastrophic claim costs.

Reinsurance Capacity

Early in 2026 with little forewarning, three reinsurers exited the medical reinsurance market, citing rising loss costs and limited visibility into a near-term return to profitability. Despite these withdrawals, the medical stop-loss reinsurance market remains adequately capitalized. Capacity is still available, but reinsurers are applying it more selectively and with greater focus on underlying profitability.

One result has been a greater emphasis on risk retention by issuing carriers. Many reinsurers now expect primary carriers to retain more individual claim risk before reinsurance coverage attaches. This shift is intended to reinforce underwriting discipline, better align incentives, and reduce excessive risk transfer.

Reinsurers are also placing increased emphasis on portfolio diversification, advanced actuarial modeling, and more detailed evaluation of pharmacy risk before deploying capacity. These considerations are becoming central to capacity decisions as high-cost therapies continue to increase claim volatility.

In addition to the reinsurers that have exited the market, some participants have reduced their participation in selected segments of the U.S. medical reinsurance market. While overall capacity remains stable, reduced competition has contributed to firmer pricing and larger-than-expected leveraged trend increases so far in 2026. With the January 1, 2027 renewal season approaching, additional pricing pressure is possible, and any further disruption in the U.S. medical reinsurance market could extend or intensify the current hard market cycle.

Specialty Pharmacy as the Primary Risk Driver

Perhaps the most transformative development affecting medical stop-loss reinsurance is the rapid expansion of specialty pharmaceuticals.

Historically, catastrophic claims often resulted from trauma, neonatal care, organ transplantation, or prolonged hospitalization. Today, specialty medications account for an increasingly large share of catastrophic healthcare expenditures.

Examples include:

- Advanced oncology biologics.
- CAR-T cell therapies for hematologic malignancies.
- Gene therapies for rare diseases.
- Treatments for autoimmune disorders.
- Glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and diabetes.

These therapies not only increase claim severity but also introduce greater uncertainty into actuarial forecasting because utilization patterns continue to evolve rapidly.

Technology and Predictive Analysis

Medical stop-loss insurers and reinsurers increasingly rely on advanced analytics to improve underwriting performance.

Artificial intelligence, predictive modeling, and machine learning applications are being incorporated into underwriting processes to identify emerging high-cost claimants earlier than traditional actuarial techniques permit.



Technology investments increasingly focus on:

- Predictive identification of catastrophic claims.
- Pharmacy utilization analysis.
- Provider network optimization.
- Clinical risk stratification.
- Fraud detection.

Organizations capable of integrating clinical expertise with sophisticated data analytics are expected to maintain a competitive advantage as claim complexity increases.

However, the results to date have been mixed and with all artificial intelligence the process needs to be reviewed to ensure errors are not occurring

Risks Facing the Industry

Despite favorable premium growth prospects, the industry faces several material risks.

First, continued medical inflation may exceed pricing assumptions, placing pressure on underwriting margins.

Second, accelerating approval of high-cost gene and cell therapies may further increase catastrophic claims beyond historical expectations. Further acceleration is likely due to cell therapies moving to second or even first line treatment, and gene therapies approved for conditions with higher prevalence in the broader population.

Third, regulatory changes affecting employer-sponsored health plans could alter demand for self-funded arrangements and stop-loss coverage.

Finally, increased competition resulting from new market entrants or alternative capital sources could compress underwriting margins if pricing discipline weakens.

The interaction between these risks creates an environment in which successful underwriting depends increasingly upon sophisticated risk selection rather than market-wide premium increases alone.

Future Outlook

The outlook for the medical stop-loss reinsurance market over the next three to five years remains favorable from a growth perspective while presenting significant underwriting challenges.

Demand for stop-loss coverage is expected to continue increasing as employers seek greater control over healthcare spending through self-funded benefit programs. Simultaneously, catastrophic claim costs are likely to continue rising due to medical innovation, demographic trends, and expanding use of specialty pharmaceuticals.

These developments are expected to support continued premium growth while reinforcing disciplined underwriting practices, higher attachment points, and stronger collaboration between insurers and reinsurers.

Organizations possessing strong actuarial capabilities, advanced predictive analytics, diversified portfolios, and disciplined pricing strategies are likely to outperform competitors during this evolving market cycle.

A robust cost containment program will be critical because stop-loss economics are increasingly shaped by a small number of high-severity claims. Even when an employer covers hundreds or thousands of members, a few claimants can determine the plan year's financial outcome. The most effective programs do not wait for claims to reach the reinsurance layer; they identify high-risk members early, support timely clinical intervention, optimize the site and cost of care, and manage claims throughout their lifecycle. This approach reduces unnecessary spending and helps improve overall results.

Integrating clinical risk management into cost containment is equally important. As specialty drugs, gene and cell therapies, and complex oncology treatments continue to increase claim severity, early identification and ongoing review of high-risk members can help promote appropriate utilization, adherence to evidence-based guidelines, and proactive management of emerging catastrophic claims. Clinical oversight can also uncover opportunities to optimize care, strengthen utilization management, review site-of-care decisions, and intervene earlier. Organizations that combine clinical expertise with data analytics and traditional cost containment strategies will be better positioned to manage rising healthcare costs and improve stop-loss performance.



Conclusion

The medical stop-loss reinsurance market is entering a new phase characterized by robust demand and heightened risk complexity. Structural growth in self-funded health plans provides a durable foundation for premium expansion, yet escalating catastrophic medical costs challenge traditional underwriting assumptions.

Future market success will depend less on premium growth alone and more on the industry's ability to accurately evaluate emerging healthcare risks, price catastrophic exposures appropriately, and leverage advanced analytics to improve underwriting performance. Although profitability may remain under pressure in the short term, disciplined insurers and reinsurers that adapt to the evolving healthcare landscape are well positioned for sustained long-term success.



About the Author



Raj Gulati

Raj Gulati brings more than 27 years of insurance and reinsurance experience to his work with insurance carriers, MGUs, health systems, hospitals, physician groups and health plans. His background includes reinsurance program design, placement, implementation, account management and customer relationship management across health, life, disability, worksite benefits and accident products.

Brown & Brown

Any solicitation or invitation to discuss insurance sales or servicing is being provided at the request of
Brown & Brown Insurance Services, Inc.,
an owned subsidiary of Brown & Brown, Inc.
Brown & Brown Insurance Services, Inc.
only provides insurance-related solicitations or services to insureds or insured risks in jurisdictions where it and its individual insurance professionals are properly licensed.

Brown & Brown, Inc. and all its affiliates, do not provide legal, regulatory or tax guidance, or advice. If legal advice counsel or representation is needed, the services of a legal professional should be sought. The information in this document is intended to provide a general overview of the topics and services contained herein. Brown & Brown, Inc. and all its affiliates, make no representation or warranty as to the accuracy or completeness of the document and undertakes no obligation to update or revise the document based upon new information or future changes.

Brown & Brown Insurance Services, Inc.
In CA: Brown & Brown Retail Insurance Services (CA Entity License #0F56560)
300 N Beach St, Daytona Beach, FL 32114 | (386) 252-6176

©2026 Brown & Brown. All rights reserved.